title: Intrinsic cardiac nervous system in tachycardia induced heart failure.
abstract: The purpose of this study was to test the hypothesis that early-stage heart failure differentially affects the intrinsic cardiac nervous system's capacity to regulate cardiac function. After 2 wk of rapid ventricular pacing in nine anesthetized canines, cardiac and right atrial neuronal function were evaluated in situ in response to enhanced cardiac sensory inputs, stimulation of extracardiac autonomic efferent neuronal inputs, and close coronary arterial administration of neurochemicals that included nicotine. Right atrial neuronal intracellular electrophysiological properties were then evaluated in vitro in response to synaptic activation and nicotine. Intrinsic cardiac nicotine-sensitive, neuronally induced cardiac responses were also evaluated in eight sham-operated, unpaced animals. Two weeks of rapid ventricular pacing reduced the cardiac index by 54%. Intrinsic cardiac neurons of paced hearts maintained their cardiac mechano- and chemosensory transduction properties in vivo. They also responded normally to sympathetic and parasympathetic preganglionic efferent neuronal inputs, as well as to locally administered alpha-or beta-adrenergic agonists or angiotensin II. The dose of nicotine needed to modify intrinsic cardiac neurons was 50 times greater in failure compared with normal preparations. That dose failed to alter monitored cardiovascular indexes in failing preparations. Phasic and accommodating neurons identified in vitro displayed altered intracellular membrane properties compared with control, including decreased membrane resistance, indicative of reduced excitability. Early-stage heart failure differentially affects the intrinsic cardiac nervous system's capacity to regulate cardiodynamics. While maintaining its capacity to transduce cardiac mechano- and chemosensory inputs, as well as inputs from extracardiac autonomic efferent neurons, intrinsic cardiac nicotine-sensitive, local-circuit neurons differentially remodel such that their capacity to influence cardiodynamics becomes obtunded.
authors.affiliation: Centre de Recherche, Hôpital du Sacré-coeur, 5400 Boulevard Gouin ouest, Montréal, QC, Canada H4J 1C5.
authors.forename: Rakesh C
authors.initials: RC
authors.lastname: Arora
authors.forename: Rene
authors.initials: R
authors.lastname: Cardinal
authors.forename: Frank M
authors.initials: FM
authors.lastname: Smith
authors.forename: Jeffrey L
authors.initials: JL
authors.lastname: Ardell
authors.forename: Louis J
authors.initials: LJ
authors.lastname: Dell'Italia
authors.forename: J Andrew
authors.initials: JA
authors.lastname: Armour
mesh_terms: D000818:Animals; D004285:Dogs; D005260:Female; D005726:Ganglia, Parasympathetic / Q000166:cytology / Q000187:drug effects / Q000502:physiology; D006321:Heart / Q000294:innervation* / Q000503:physiopathology*; D006333:Heart Failure / Q000503:physiopathology*; D066298:In Vitro Techniques; D008297:Male; D008564:Membrane Potentials / Q000187:drug effects; D009474:Neurons / Q000187:drug effects / Q000502:physiology; D009538:Nicotine / Q000494:pharmacology; D018722:Nicotinic Agonists / Q000494:pharmacology; D010138:Pacemaker, Artificial; D010812:Physical Stimulation; D013268:Stimulation, Chemical; D013564:Sympathetic Nervous System / Q000187:drug effects / Q000502:physiology; D013610:Tachycardia / Q000503:physiopathology*; D014701:Veratridine / Q000494:pharmacology
chemical_list: D018722:Nicotinic Agonists; D009538:Nicotine; D014701:Veratridine